Next Article in Journal
The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air
Next Article in Special Issue
Protective Vaccination Reshapes Hepatic Response to Blood-Stage Malaria of Genes Preferentially Expressed by NK Cells
Previous Article in Journal
Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers
Article

Xanthohumol and Gossypol Are Promising Inhibitors against Babesia microti by In Vitro Culture via High-Throughput Screening of 133 Natural Products

by 1,2, 3, 1,2, 1,2,4,* and 1,2,4
1
State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China
2
Key Laboratory of Preventive Veterinary Medicine in Hubei Province, Wuhan 430070, China
3
College of Animal Sciences, Fujian Agriculture and Forestry University, Fuzhou 350000, China
4
Key Laboratory of Animal Epidemical Disease and Infectious Zoonoses, Ministry of Agriculture, Huazhong Agricultural University, Wuhan 430070, China
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 613; https://doi.org/10.3390/vaccines8040613
Received: 16 July 2020 / Revised: 6 October 2020 / Accepted: 13 October 2020 / Published: 16 October 2020
(This article belongs to the Special Issue Advances in Parasite Vaccines)
Human babesiosis caused by Babesia microti is an emerging threat for severe illness and even death, with an increasing impact worldwide. Currently, the regimen of atovaquone and azithromycin is considered as the standard therapy for treating human babesiosis, which, however, may result in drug resistance and relapse, suggesting the necessity of developing new drugs to control B. microti. In this regard, natural products are promising candidates for drug design against B. microti due to their active therapeutic efficacy, lower toxicity, and fewer adverse reactions to host. Here, the potential inhibitors against B. microti were preliminarily screened from 133 natural products, and 47 of them were selected for further screening. Gossypol (Gp) and xanthohumol (Xn) were finally shown to effectively inhibit the growth of B. microti with IC50 values of 8.47 μm and 21.40 μm, respectively. The cytotoxicity results showed that Gp and Xn were non-toxic to erythrocytes at a concentration below 100 μm. Furthermore, both of them were confirmed to be non-toxic to different types of cells in previous studies. Our findings suggest the potential of Gp and Xn as effective drugs against B. microti infection. View Full-Text
Keywords: human babesiosis; Babesia microti; natural products; gossypol; xanthohumol human babesiosis; Babesia microti; natural products; gossypol; xanthohumol
Show Figures

Figure 1

MDPI and ACS Style

Guo, J.; Luo, X.; Wang, S.; He, L.; Zhao, J. Xanthohumol and Gossypol Are Promising Inhibitors against Babesia microti by In Vitro Culture via High-Throughput Screening of 133 Natural Products. Vaccines 2020, 8, 613. https://doi.org/10.3390/vaccines8040613

AMA Style

Guo J, Luo X, Wang S, He L, Zhao J. Xanthohumol and Gossypol Are Promising Inhibitors against Babesia microti by In Vitro Culture via High-Throughput Screening of 133 Natural Products. Vaccines. 2020; 8(4):613. https://doi.org/10.3390/vaccines8040613

Chicago/Turabian Style

Guo, Jiaying, Xiaoying Luo, Sen Wang, Lan He, and Junlong Zhao. 2020. "Xanthohumol and Gossypol Are Promising Inhibitors against Babesia microti by In Vitro Culture via High-Throughput Screening of 133 Natural Products" Vaccines 8, no. 4: 613. https://doi.org/10.3390/vaccines8040613

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop